TScan Therapeutics, Inc. (TCRX) Misses Q4 EPS by 1c

TScan Therapeutics, Inc. (NASDAQ: TCRX) reported Q4 EPS of ($0.30), $0.01 worse than the analyst estimate of ($0.29). Revenue for the quarter came in at $670 thousand versus the consensus estimate of $1.51 million.

For earnings history and earnings-related data on TScan Therapeutics, Inc. (TCRX) click here.

You May Also Be Interested In

• Walmart (WMT) Tops Q2 EPS by 7c, Beats on Revenue; Offers FY27 EPS Guidance
• Advance Auto Parts (AAP) Tops Q2 EPS by 22c; lifrs profit guidance
• Youdao, Inc. (DAO) Tops Q2 EPS by 50c